Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns

Evaluation and definition of response and progression from trials to clinical practice